Results 211 to 220 of about 1,231,536 (373)

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source

Referral to Medical Oncology: A Crucial Step in the Treatment of Older Patients with Stage III Colon Cancer [PDF]

, 2006
RuiLi Luo, Sharon H. Giordano, Jean L. Freeman, Dong Zhang, James S. Goodwin   +4 more
openalex   +1 more source

Addressing the Oncologist Shortage in Latin America: Insights From a Survey of Medical Oncology Fellowship Programs. [PDF]

JCO Glob Oncol
Zegarra-López M, Aranda-Gutierrez A, Muñoz Lozano JF, Villarreal-Garza C.   +3 more
europepmc   +1 more source

The Impact of NUTRItional Status at First Medical Oncology Visit on Clinical Outcomes: The NUTRIONCO Study. [PDF]

Cancers (Basel), 2023
Muscaritoli M, Modena A, Valerio M, Marchetti P, Magarotto R, Quadrini S, Narducci F, Tonini G, Grassani T, Cavanna L, Di Nunzio C, Citterio C, Occelli M, Strippoli A, Chiurazzi B, Frassoldati A, Altavilla G, Lucenti A, Nicolis F, Gori S.   +19 more
europepmc   +1 more source

Importance of three-dimensional treatment planning and dose-volume histogram analysis in the performance and evaluation of intravascular brachytherapy Louis B. Harrison, Akiko Maehara, Neil S. Patel, Neil J. Weissman, Ron Waksman, Gary S. Mintz, Taya L. McMillan, Julianna Pisch, Harry Quon, Nathan Yang, Rosanna Chan, Huchen Xie, Sou-Tung Chiu-Tsao. Department of Radiation Oncology, Beth Israel Medical Center & St. Luke's-Roosevelt Hospital Center, New York, NY, Cardiovascular Research …

, 2001

openalex   +1 more source

Images in clinical medicine. Bilateral ovarian dermoid cysts. [PDF]

, 2001
Boulay, Richard, MD, Podczaski, E
core   +1 more source

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

Workforce Trends Among Canadian Medical Oncologists and Medical Oncology Trainees over Two Decades. [PDF]

Curr Oncol
Fundytus A, Cook S, Yip SM, Loewen SK, Hao D.   +4 more
europepmc   +1 more source

Twice-daily pain monitoring as standard clinical practice for inpatients at a medical oncology unit: a descriptive study [PDF]

, 2006
A. Martoni, Claudia Degli Esposti, A. Cricca, Guido Rocchi, S. Giaquinta   +4 more
openalex   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source